加载中
NASDAQHealthcareBiotechnology
最新数据
US$0.4671
−US$0.002 · -0.43%
Bone Biologics Corporation, a medical device enterprise, specializes in fostering bone regeneration for spinal fusion, leveraging its advanced recombinant human protein technology. Its flagship product, NELL-1/DBX, is a unique combination of an osteostimulative recombinant protein designed for precise, targeted control over bone regrowth. The company is currently advancing the NELL-1/DBX Fusion Device, intended for spinal fusion interventions in skeletally mature individuals experiencing single-level degenerative disc disease within the L4-S1 spinal segments. This versatile platform technology also holds the potential to deliver superior outcomes across a wide spectrum of surgical specialties, including spinal, various orthopedic fields, plastic reconstruction, neurosurgery, interventional radiology, and sports medicine. Bone Biologics holds a licensing agreement with the UCLA Technology Development Group, which authorizes the development and commercialization of NELL-1 for its spinal fusion applications. The firm was established in 2004 and is based in Burlington, Massachusetts.
前收盘价
US$0.4671
−US$0.002 · -0.43%
盘中时间采用ET。市场数据可能有所延迟。
Bone Biologics Corporation, a medical device enterprise, specializes in fostering bone regeneration for spinal fusion, leveraging its advanced recombinant human protein technology. Its flagship product, NELL-1/DBX, is a unique combination of an osteostimulative recombinant protein designed for precise, targeted control over bone regrowth. The company is currently advancing the NELL-1/DBX Fusion Device, intended for spinal fusion interventions in skeletally mature individuals experiencing single-level degenerative disc disease within the L4-S1 spinal segments. This versatile platform technology also holds the potential to deliver superior outcomes across a wide spectrum of surgical specialties, including spinal, various orthopedic fields, plastic reconstruction, neurosurgery, interventional radiology, and sports medicine. Bone Biologics holds a licensing agreement with the UCLA Technology Development Group, which authorizes the development and commercialization of NELL-1 for its spinal fusion applications. The firm was established in 2004 and is based in Burlington, Massachusetts.
日内区间
当前US$0.4671
52周区间
当前US$0.4671
盘中时间采用ET。市场数据可能有所延迟。
GoAI 评分
卖出
估值
50
合理估值
情绪
56
多空交织
风险
70
高风险
动量
35
动能减弱
完整 GoAI 研究
继续查看更深入的依据、催化因素和风险。
Bone Biologics Corporation, a medical device enterprise, specializes in fostering bone regeneration for spinal fusion, leveraging its advanced recombinant human protein technology. Its flagship product, NELL-1/DBX, is a unique combination of an osteostimulative recombinant protein designed for precise, targeted control over bone regrowth. The company is currently advancing the NELL-1/DBX Fusion Device, intended for spinal fusion interventions in skeletally mature individuals experiencing single-level degenerative disc disease within the L4-S1 spinal segments. This versatile platform technology also holds the potential to deliver superior outcomes across a wide spectrum of surgical specialties, including spinal, various orthopedic fields, plastic reconstruction, neurosurgery, interventional radiology, and sports medicine. Bone Biologics holds a licensing agreement with the UCLA Technology Development Group, which authorizes the development and commercialization of NELL-1 for its spinal fusion applications. The firm was established in 2004 and is based in Burlington, Massachusetts.
日内区间
当前US$0.4671
52周区间
当前US$0.4671
营业利润
净利润
| 项目（USD） | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 研究与开发 | 106.02万 USD | 213万 USD | 690.8万 USD | 157.93万 USD | 8.2万 USD |
| 销售、一般及管理费用 | 217.48万 USD | 208.9万 USD | 252万 USD | 208.59万 USD | 102.1万 USD |
| 营业费用 | 323.49万 USD | 421.9万 USD | 942.8万 USD | 366.52万 USD | 110.31万 USD |
| 利息收入 | 12.2万 USD | 5.57万 USD | 1868 USD | — | 805.11 USD |
| 利息支出 | — | — | — | 73.17万 USD | 80.51万 USD |
| 折旧和摊销 | — | 421.92万 USD | 942.83万 USD | — | — |
| 营业利润 | −323.49万 USD | −421.9万 USD | −942.8万 USD | −366.52万 USD | −110.31万 USD |
| 净利润 | −310.9万 USD | −411.2万 USD | −894.9万 USD | −148.46万 USD | −161.07万 USD |
公司数据更新于 2026年10月11日。
已公布业绩及可用的市场共识预期。
已公布业绩及可用的市场共识预期。
AI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
